ACC.24: Late-Breaking Science Video Collection
Published: 06 April 2024
-
Views:
5943
-
Likes:
7
-
Views:
5943
-
Likes:
7
-
Up Next -
5m 41sPart 3 | Session 7 Self-Expanding vs Balloon Expandable TAVR: The SMART Trial -
3m 37s -
4m 35sPart 3 | Session 9 Technology-Assisted Nonprescription Rosuvastatin: TACTiC -
4m 45sPart 3 | Session 10 Coronary Sinus Reducer in Refractory Angina: ORBITA COSMIC -
2m 30sPart 3 | Session 11 TAVI Vs SAVR in Patients with Severe Aortic Valve Stenosis: DEDICATE-DZHK6 -
4m 17s
-
6m 45sPart 4 | Session 1 Artificial Intelligence in Cardiology: What You Need to Know in 2024 -
6m 21sPart 4 | Session 2 Weight Loss Medications: What You Need to Know in 2024
-
43m 48sPart 1 | Session 1 ACC.24 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
28m 9sPart 1 | Session 2 What's Hot at ACC.24? Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
22m 43sPart 2 | Session 1 Late-Breaker Discussion: The EMPACT-MI Trial Harriette Van Spall, Javed Butler
-
14m 7sPart 2 | Session 2 Late-Breaker Discussion: The AEGIS-II Trial Michael C Gibson, Harriette Van Spall
-
29m 8sPart 2 | Session 3 Late-Breaker Discussion: The RELIEVE-HF Trial Gregg Stone, Harriette Van Spall
-
23m 6sPart 2 | Session 4 Late-Breaker Discussion: The ARISE-HF Trial Harriette Van Spall, James L Januzzi
-
5m 50sPart 3 | Session 1 Gamification and Financial Incentives to Increase PA Among Patients at Elevated Cardiovascular Risk Alexander Fanaroff
-
7m 49sPart 3 | Session 2 Zilbesiran in Patients With Hypertension: KARDIA-2 Akshay S Desai
-
3m 40sPart 3 | Session 3 Olezarsen in Adults with Hypertriglyceridemia and ASCVD and/or Severe Hypertriglyceridemia Brian Bergmark
-
7m 18sPart 3 | Session 4 Lerodalcibep in Patients With High Risk For Cardiovascular Disease on Stable Lipid-Lowering Therapy Evan A Stein
-
6m 40sPart 3 | Session 5 Chelation Therapy in Post-MI Pts with Diabetes: TACT2 Gervasio L Lamas
Overview
Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.
To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.
For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
More from this programme
Part 1
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24.
Part 2
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principal investigators for discussion on selected late-breaking trials.
Part 3
Expert Interviews
Expert Interviews conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.
Part 4
Highlights
Part 5
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
About the episode
ACC.24 — We are joined onsite by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF DM Trial (NCT04916470).
The STEP HFpEF DM study aimed to investigate the effect of taking semaglutide 2.4mg once weekly in patients with heart failure with preserved ejection fraction (HFpEF) and diabetes mellitus type 2. The study looked at the impact of heart failure on participants daily life, as well as change in body weight. 610 patients were enrolled in the study, and received either semaglutide or placebo once a week, for 59 weeks.
Findings showed that semaglutide 2.4 mg produced larger reductions in HF-related symptoms and physical limitations, greater weight loss and greater improvements in exercise function than placebo in patients with obesity-related HFpEF and type 2 diabetes. During the study, lower NT-proBNP rates were observed, with fewer HF events as compared to placebo. The drug was well tolerated, and reduced HbA1c without an increase in clinically significant hypoglycaemia or diabetic retinopathy events.
Interview Questions:
- What is the importance of this study?
- What was the study design and patient population?
- What are your key findings?
- What are the implications of these findings on clinical practice?
- What are your take-home messages?
- What questions remain around semaglutide?
Recorded onsite at the ACC Conference in Atlanta, 2024.
Faculty Biographies
Mikhail Kosiborod
Cardiologist
Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.
He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.
Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.
Comments